Physician profile
Mark L Malton
NPI 1629068283
$2,812.89
in general payments reported to CMS, 2019-2025
18 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $477 · 2020: $252 · 2021: $172 · 2022: $595 · 2023: $402 · 2024: $780 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,317.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $813.55 | 2019-2022 | |
| Horizon Therapeutics Plc | $441.93 | 2020-2023 | Tepezza |
| Amgen INC. | $394.83 | 2024-2025 | Tepezza |
| Alcon Vision LLC | $311.97 | 2019-2024 | Clareon, Lensx |
| Tarsus Pharmaceuticals, INC. | $307.82 | 2024-2025 | Xdemvy |
| New World Medical,INC. | $132.23 | 2024 | Clearpath, Kahook Dual Blade, Ahmed Glaucoma Valve |
| Omeros Corporation | $125.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $53.54 | 2022-2023 | |
| Bausch & Lomb Americas INC. | $42.86 | 2022 | |
| Harrow Eye, LLC | $34.49 | 2024 | Vevye |
| Abbvie INC. | $29.10 | 2023 | |
| Aerie Pharmaceuticals, INC. | $22.66 | 2019 | |
| Rxsight INC | $21.34 | 2024 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Allergan, INC. | $20.04 | 2022 | |
| Merz North America, INC. | $19.82 | 2023 | Xeomin |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $15.50 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $15.45 | 2019 | |
| Notal Vision, INC. | $10.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$17,869.91 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Malton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.